This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Rheumatoid Arthritis (RA)
and you are
over 18
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The comparison of safety and efficacy of upadacitinib versus abatacept in participants with rheumatoid arthritis on a stable background conventional synthetic Disease Modifying Anti-Rheumatic Drug (csDMARD) who have an inadequate response or intolerance to biologic DMARDs.

Provided treatments

  • Drug: Upadacitinib matching placebo
  • Drug: Abatacept matching placebo
  • Drug: Upadacitinib
  • Drug: Abatacept

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03086343. The sponsor of the trial is AbbVie and it is looking for 614 volunteers for the current phase.
Official trial title:
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)